REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms > Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Tetracyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos Tetracyclo Ring System Having The Six-membered Hetero Ring As One Of The CyclosTetracyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027176 - Compositions for veterinary and medical applications for the treatment of gastrointestinal functional disorders or related conditions; as well as for the promotion of general health and weight gain in animals including humans. ... // - 30 - ... // - 100 - ... // - 1 - ... // - 1 - ... // - 1 - ... // - 1 - ... 01/25/07 - 20070021455 - Process for the preparation of finasteride form i A process of preparing finasteride Form (I), which process comprises dissolving finasteride in a solvent, replacing the solvent partially or substantially completely with a nonsolvent and thereafter isolating finasteride Form (I). There is also provided finasteride Form (I) prepared in accordance with the present invention, and the therapeutic use thereof ... 12/21/06 - 20060287349 - 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, ... 12/21/06 - 20060287348 - 17-acetamido-4-azasteroid derivatives as androgen receptor modulators Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. ... 10/05/06 - 20060223838 - Methods and compositions for the treatment of hyperlipidemia Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, ... 07/06/06 - 20060148838 - Novel pyrrolodihydroisoquinolines useful in the treatment of cancer The invention relates to novel pyrrolodihydroisoquinoline derivatives, which are efficacious inhibitors of cellular (hyper)proliferation and/or inducers of apoptosis in cancer cells. ... 04/20/06 - 20060084671 - Process for the preparation of pure finasteride which comprises converting dihydrofinasteride to finasteride through novel protected dihydrofinasteride and protected finasteride intermediates. ... 03/09/06 - 20060052409 - Therapeutic or preventive agent for nausea/vomiting or a pharmacologically acceptable acid addition salt thereof as an active ingredient. The compounds are useful as therapeutic or prophylactic agents for preventing nausea and vomiting caused by μ-agonists represented by, morphine. ... 01/26/06 - 20060019980 - Methods for treating or preventing erectile dysfunction or urinary incontinence The present invention relates to methods for treating or preventing erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a compound of the invention. ... 01/26/06 - 20060019979 - Method for the selective preparation of 3-oxo-4-aza-5a androstane compound This invention relates to a method for selectively preparing the 3-oxo-4-aza-5¥á-androstane compound which is used as an intermediate of finasteride by heating 3-oxo-4-aza-5-androstene in a mixture of formic acid and an alkanediol in the presence of zinc. ... 12/22/05 - 20050282848 - Isoquinoline derivatives and methods of use thereof The invention provides novel classes of Isoquinoline Derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described. ... 10/13/05 - 20050228008 - Process for obtaining the polymorphic form i of finasteride The process includes the steps of (i) dissolving finasteride in a substantially anhydrous organic solvent selected among n-butyl acetate, iso-butyl acetate, sec-butyl acetate, tert-butyl acetate, C5 alkyl acetate and mixtures thereof, at a temperature equal to or lower than the boiling point of said organic solvent; (ii) slowly cooling said ... 10/13/05 - 20050228007 - Isoquinoline derivatives and methods of use thereof The present invention relates to Isoquinoline Derivatives, compositions comprising an effective amount of a Isoquinoline Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease other than a cardiovascular disease, cardiovascular disease, reoxygenation injury resulting ... 08/18/05 - 20050182082 - Modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1-X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of ... 08/04/05 - 20050171136 - Modulators of the glucocorticoid receptor and method where Z is CONR1R2 or CH2NR1R2 and where R, Ra, Rb, Rc, Rd, Z, A and B are defined herein. ... 07/28/05 - 20050165039 - Fluorinated 4-azasteroid derivatives as androgen receptor modulators Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. ... 07/07/05 - 20050148616 - Inhibitor of tnf-alpha and il-1beta production wherein each of R1, R2, R3, and R4, independently, is H, alkyl, aryl, or alkylcarbonyl, or R1 and R2 together, or R3 and R4 together are —(CH2)n—, n being 1, 2, or 3. Also disclosed is a method of treating a TNF-α or IL-1β related disorder using such a compound. ... 06/30/05 - 20050143408 - Aporphine esters and their use in therapy New aporphine derivatives are disclosed which have formula (I) and the physiologically acceptable salts thereof. Said derivatives may be used for the treatment of Parkinson's disease, hemicrania, restless legs syndrome (RLS), sexual dysfunction in men and women, hyperprolactemia and psychotic disorders, and/or evaluation of Parkinson's disease. Processes for the preparation ... 06/16/05 - 20050131005 - 4-azasteroid derivatives as androgen receptor modulators Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. ... 06/09/05 - 20050124643 - Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase A sulphamate compound suitable for use as an inhibitor of oestrone sulphatase (E.C.3.1.6.2) is described. The compound is a polycyclic compound comprising at least two ring components, wherein the polycyclic compound comprises at least one sulphamate group attached to at least one of the ring components, and wherein at least ... ### FreshPatents.com Support |